November 13, 2007 presentation by Edgar Engleman for the Stanford School of Medicine Medcast lecture series. Edgar Engleman, MD, medical director of the Stanford Blood Center, discusses his research involving the use of a special type of white blood cell as a treatment for cancer. Engleman, who is also a professor of pathology at the Stanford School of Medicine, and his team of researchers have been interested in dendritic cells, or DCs, which can provoke an immune response in the body. Stanford University School of Medicine: med.stanford.edu Stanford University Channel on YouTube: www.youtube.com
The FDA and Pharma are in bed together. Polyclonal antibodies would be much more efficient therapeutically. They know very well that the body is too complex too respond to single agent drugs and drug targets. Its their narrow-minded (possibly deliberate) stubborness that is stifling progress in cancer therapy. They WANT to keep chemo as standard therapy. Why? Because using chemo makes this industry a $200 billion per year industry. The drugs required to manage side effects are several, & pricey